The DOI matches its Crossref record; 120 of the 120 references it cites were found in a registry or an index.
Obesity: Current and potential pharmacotherapeutics and targets
Open accessAbstract
Obesity is a global epidemic that contributes to a number of health complications including cardiovascular disease, type 2 diabetes, cancer and neuropsychiatric disorders. Pharmacotherapeutic strategies to treat obesity are urgently needed. Research over the past two decades has increased substantially our knowledge of central and peripheral mechanisms underlying homeostatic energy balance. Homeostatic mechanisms involve multiple components including neuronal circuits, some originating in hypothalamus and brain stem, as well as peripherally‐derived satiety, hunger and adiposity signals that modulate neural activity and regulate eating behavior. Dysregulation of one or more of these homeostatic components results in obesity. Coincident with obesity, reward mechanisms that regulate hedonic aspects of food intake override the homeostatic regulation of eating. In addition to functional interactions between homeostatic and reward systems in the regulation of food intake, homeostatic signals have the ability to alter vulnerability to drug abuse. Regarding the treatment of obesity, pharmacological monotherapies primarily focus on a single protein target. FDA‐approved monotherapy options include phentermine (Adipex‐P®), orlistat (Xenical®), lorcaserin (Belviq®) and liraglutide (Saxenda®). However, monotherapies have limited efficacy, in part due to the recruitment of alternate and counter‐regulatory pathways. Consequently, a multi‐target approach may provide greater benefit. Recently, two combination products have been approved by the FDA to treat obesity, including phentermine/topiramate (Qsymia®) and naltrexone/bupropion (Contrave®). The current review provides an overview of homeostatic and reward mechanisms that regulate energy balance, potential therapeutic targets for obesity and current treatment options, including some candidate therapeutics in clinical development. Finally, challenges in anti‐obesity drug development are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Child abuse: Adolescent records vs. adult recall
Femina, D. D., Yeager, C. A., & Lewis, D. O. (1990) · Child Abuse & Neglect · doi:10.1016/0145-2134(90)90033-p · Cited by 8,820
Central nervous system control of food intake
Schwartz, M. W., Woods, S. C., Porte, D., Seeley, R. J., & Baskin, D. G. (2000) · Nature · doi:10.1038/35007534 · Cited by 6,451
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Sakurai, T., Amemiya, A., Ishii, M., Matsuzaki, I., Chemelli, R. M., Tanaka, H., Williams, S. C., Richardson, J. A., Kozlowski, G. P., Wilson, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)80949-6 · Cited by 5,501 · cited 32×
“Both orexin receptor subtypes, orexin-1 and orexin-2, are located in reward relevant brain regions including DA projections from VTA to accumbens, prefrontal cortex and amygdala (Sakurai et al., 1998; Marcus et al., 2001).”
InfluentialParadoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity
Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J.-I., Hotta, K., Shimomura, I., Nakamura, T., Miyaoka, K., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0255 · Cited by 4,856
What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?
Berridge, K. C., & Robinson, T. E. (1998) · Brain Research Reviews · doi:10.1016/s0165-0173(98)00019-8 · Cited by 4,127
The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity
de Lecea, L., Kilduff, T. S., Peyron, C., Gao, X.-B., Foye, P. E., Danielson, P. E., Fukuhara, C., Battenberg, E. L. F., Gautvik, V. T., Bartlett, F. S., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.1.322 · Cited by 3,878
Neural systems of reinforcement for drug addiction: from actions to habits to compulsion
Everitt, B. J., & Robbins, T. W. (2005) · Nature Neuroscience · doi:10.1038/nn1579 · Cited by 3,785
Neurons containing hypocretin (orexin) project to multiple neuronal systems
Peyron, C., Tighe, D. K., van den Pol, A. N., de Lecea, L., Heller, H. C., Sutcliffe, J. G., & Kilduff, T. S. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-23-09996.1998 · Cited by 3,466
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
Cloning of adiponectin receptors that mediate antidiabetic metabolic effects
Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M., et al. (2003) · Nature · doi:10.1038/nature01705 · Cited by 3,176 · cited 2×
“Two distinct adiponectin receptors, adipoR1 and adipoR2, are expressed highly in skeletal muscle and liver, respectively, and in hypothalamus (Yamauchi et al., 2003; Qi et al., 2004).”
Targeted disruption of the melanocortin-4 receptor results in obesity in mice
Huszar, D., Lynch, C. A., Fairchild-Huntress, V., Dunmore, J. H., Fang, Q., Berkemeier, L. R., Gu, W., Kesterson, R. A., Boston, B. A., Cone, R. D., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)81865-6 · Cited by 3,030
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans
Cummings, D. E., Purnell, J. Q., Frayo, R. S., Schmidova, K., Wisse, B. E., & Weigle, D. S. (2001) · Diabetes · doi:10.2337/diabetes.50.8.1714 · Cited by 2,940 · cited 2×
“Ghrelin levels are dependent on nutritional status such that peak levels occur prior to meal initiation, followed by a decrease in levels upon food consumption (Cummings et al., 2001; Callahan et al., 2004).”
Vrieze, A., Van Nood, E., Holleman, F., Salojärvi, J., Kootte, R. S., Bartelsman, J. F. W. M., Dallinga–Thie, G. M., Ackermans, M. T., Serlie, M. J., Oozeer, R., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.031 · Cited by 2,913
U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, & U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-79 · Cited by 2,856
The adipocyte-secreted protein Acrp30 enhances hepatic insulin action
Berg, A. H., Combs, T. P., Du, X., Brownlee, M., & Scherer, P. E. (2001) · Nature Medicine · doi:10.1038/90992 · Cited by 2,526
Leptin activates anorexigenic POMC neurons through a neural network in the arcuate nucleus
Cowley, M. A., Smart, J. L., Rubinstein, M., Cerdán, M. G., Diano, S., Horvath, T. L., Cone, R. D., & Low, M. J. (2001) · Nature · doi:10.1038/35078085 · Cited by 2,356
Abnormal splicing of the leptin receptor in diabetic mice
Lee, G.-H., Proenca, R., Montez, J. M., Carroll, K. M., Darvishzadeh, J. G., Lee, J. I., & Friedman, J. M. (1996) · Nature · doi:10.1038/379632a0 · Cited by 2,327
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Nucleus locus ceruleus: new evidence of anatomical and physiological specificity
Foote, S. L., Bloom, F. E., & Aston-Jones, G. (1983) · Physiological Reviews · doi:10.1152/physrev.1983.63.3.844 · Cited by 1,901
TGR5-Mediated Bile Acid Sensing Controls Glucose Homeostasis
Thomas, C., Gioiello, A., Noriega, L., Strehle, A., Oury, J., Rizzo, G., Macchiarulo, A., Yamamoto, H., Mataki, C., Pruzanski, M., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.08.001 · Cited by 1,885
Wang, G.-J., Volkow, N. D., Logan, J., Pappas, N. R., Wong, C. T., Zhu, W., Netusll, N., & Fowler, J. S. (2001) · The Lancet · doi:10.1016/s0140-6736(00)03643-6 · Cited by 1,864 · cited 1×
“In obese humans, striatal DA D2 receptor density is decreased in comparison to non-obese individuals (Wang et al., 2001; Stice et al., 2008).”
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
Differential expression of orexin receptors 1 and 2 in the rat brain
Marcus, J. N., Aschkenasi, C. J., Lee, C. E., Chemelli, R. M., Saper, C. B., Yanagisawa, M., & Elmquist, J. K. (2001) · Journal of Comparative Neurology · doi:10.1002/cne.1190 · Cited by 1,659
A G Protein-coupled Receptor Responsive to Bile Acids
Kawamata, Y., Fujii, R., Hosoya, M., Harada, M., Yoshida, H., Miwa, M., Fukusumi, S., Habata, Y., Itoh, T., Shintani, Y., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209706200 · Cited by 1,628
Relationship between stress, eating behavior, and obesity
Torres, S. J., & Nowson, C. A. (2007) · Nutrition · doi:10.1016/j.nut.2007.08.008 · Cited by 1,622
The reinstatement model of drug relapse: history, methodology and major findings
Shaham, Y., Shalev, U., Lu, L., de Wit, H., & Stewart, J. (2003) · Psychopharmacology · doi:10.1007/s00213-002-1224-x · Cited by 1,615
Interacting Appetite-Regulating Pathways in the Hypothalamic Regulation of Body Weight
Kalra, S. P. (1999) · Endocrine Reviews · doi:10.1210/er.20.1.68 · Cited by 1,554
Preliminary validation of the Yale Food Addiction Scale
Gearhardt, A. N., Corbin, W. R., & Brownell, K. D. (2009) · Appetite · doi:10.1016/j.appet.2008.12.003 · Cited by 1,369
Yin, H. H., Knowlton, B. J., & Balleine, B. W. (2004) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2004.03095.x · Cited by 1,226
Yang, W.-S., Lee, W.-J., Funahashi, T., Tanaka, S., Matsuzawa, Y., Chao, C.-L., Chen, C.-L., Tai, T.-Y., & Chuang, L.-M. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.8.3815 · Cited by 1,181
Changes in brain activity related to eating chocolate: From pleasure to aversion
Small, D. M. (2001) · Brain · doi:10.1093/brain/124.9.1720 · Cited by 1,179 · cited 1×
“Insula is involved in processing and evaluation of food cues and in craving for food (Small et al., 2001; Pelchat et al., 2004).”
Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons
Hahn, T. M., Breininger, J. F., Baskin, D. G., & Schwartz, M. W. (1998) · Nature Neuroscience · doi:10.1038/1082 · Cited by 1,164
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 1×
“In Europe, rimonabant was used as an adjunct to diet and exercise for the treatment of obesity (Christensen et al., 2007).”
How can drug addiction help us understand obesity?
Volkow, N. D., & Wise, R. A. (2005) · Nature Neuroscience · doi:10.1038/nn1452 · Cited by 1,089
Mechanisms of leptin action and leptin resistance.
Myers, M. G., Cowley, M. A., & Münzberg, H. (2008) · Annual Review of Physiology · doi:10.1146/annurev.physiol.70.113006.100707 · Cited by 1,074
Gadde, K. M., Allison, D. B., Ryan, D. H., Peterson, C. A., Troupin, B., Schwiers, M. L., & Day, W. W. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60205-5 · Cited by 1,064
Avenell, A., Broom, J., Brown, T., Poobalan, A., Aucott, L., Stearns, S., Smith, W., Jung, R., Campbell, M., & Grant, A. (2004) · Health Technology Assessment · doi:10.3310/hta8210 · Cited by 1,041 · cited 1×
“A 5-10% weight loss reduces the incidence of both type 2 diabetes and cardiovascular complications (Avenell et al., 2004).”
Abizaid, A., Liu, Z.-W., Andrews, Z. B., Shanabrough, M., Borok, E., Elsworth, J. D., Roth, R. H., Sleeman, M. W., Picciotto, M. R., Tschöp, M. H., et al. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29867 · Cited by 984 · cited 4×
“…intra-VTA infusions of GHSR antagonist, BIM28163 (4-[[(2S)-2-[[(2R)-2-[[(2R)-3-(1-benzothiophene-3-yl)-2-(piperidine-3carbonylamino)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-3phenylpropanoyl]amino]piperidine-4-carboxamide; 0.5 μg/0.5 μl) given 1 h prior to ghrelin (Abizaid et al., 2006).”
InfluentialSorting out the roles of PPAR in energy metabolism and vascular homeostasis
Lefebvre, P. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27989 · Cited by 962
Kelley, A. E. (2004) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2003.11.015 · Cited by 942
Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith, S. R., Weissman, N. J., Anderson, C. M., Sanchez, M., Chuang, E., Stubbe, S., Bays, H., & Shanahan, W. R. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909809 · Cited by 911 · cited 1×
“In contrast to fenfluramine, no increase in rate of cardiac valvulopathy was found after a 2-year lorcaserin treatment (Smith et al., 2010).”
Leptin Receptor Signaling in Midbrain Dopamine Neurons Regulates Feeding
Hommel, J. D., Trinko, R., Sears, R. M., Georgescu, D., Liu, Z.-W., Gao, X.-B., Thurmon, J. J., Marinelli, M., & DiLeone, R. J. (2006) · Neuron · doi:10.1016/j.neuron.2006.08.023 · Cited by 902
Brain-derived neurotrophic factor regulates energy balance downstream of melanocortin-4 receptor
Xu, B., Goulding, E. H., Zang, K., Cepoi, D., Cone, R. D., Jones, K. R., Tecott, L. H., & Reichardt, L. F. (2003) · Nature Neuroscience · doi:10.1038/nn1073 · Cited by 896
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Glenn Stanley, B., Kyrkouli, S. E., Lampert, S., & Leibowitz, S. F. (1986) · Peptides · doi:10.1016/0196-9781(86)90149-x · Cited by 849
Overlapping neuronal circuits in addiction and obesity: evidence of systems pathology
Volkow, N. D., Wang, G.-J., Fowler, J. S., & Telang, F. (2008) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2008.0107 · Cited by 809 · cited 5×
“Hedonic properties of palatable foods and addictive drugs are regulated in brain by a common reward circuitry, such that excessive consumption of palatable foods and drugs produces similar neuroadaptation (Volkow et al., 2008, 2012; Kenny, 2011).”
InfluentialAdiponectin acts in the brain to decrease body weight
Qi, Y., Takahashi, N., Hileman, S. M., Patel, H. R., Berg, A. H., Pajvani, U. B., Scherer, P. E., & Ahima, R. S. (2004) · Nature Medicine · doi:10.1038/nm1029 · Cited by 809
BDNF regulates eating behavior and locomotor activity in mice
Kernie, S. G., Liebl, D. J., & Parada, L. F. (2000) · The EMBO Journal · doi:10.1093/emboj/19.6.1290 · Cited by 806
Broberger, C., Johansen, J., Johansson, C., Schalling, M., & Hökfelt, T. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.15043 · Cited by 798
Stice, E., Spoor, S., Bohon, C., Veldhuizen, M. G., & Small, D. M. (2008) · Journal of Abnormal Psychology · doi:10.1037/a0013600 · Cited by 779 · cited 1×
“In obese humans, striatal DA D2 receptor density is decreased in comparison to non-obese individuals (Wang et al., 2001; Stice et al., 2008).”
Drug treatments for obesity: orlistat, sibutramine, and rimonabant
Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753
Multiple neural systems controlling food intake and body weight
Berthoud, H.-R. (2002) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(02)00014-3 · Cited by 725
Berridge, K. (2000) · Neuroscience & Biobehavioral Reviews · doi:10.1016/s0149-7634(99)00072-x · Cited by 721
Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats
Obici, S., Feng, Z., Karkanias, G., Baskin, D. G., & Rossetti, L. (2002) · Nature Neuroscience · doi:10.1038/nn0602-861 · Cited by 719
Garvey, W. T., Ryan, D. H., Look, M., Gadde, K. M., Allison, D. B., Peterson, C. A., Schwiers, M., Day, W. W., & Bowden, C. H. (2012) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.111.024927 · Cited by 716
Li, F., Jiang, C., Krausz, K. W., Li, Y., Albert, I., Hao, H., Fabre, K. M., Mitchell, J. B., Patterson, A. D., & Gonzalez, F. J. (2013) · Nature Communications · doi:10.1038/ncomms3384 · Cited by 705 · cited 1×
“Mice with intestine-specific FXR deletion are resistant to DIO (Li et al., 2013).”
Images of desire: food-craving activation during fMRI
Pelchat, M. L., Johnson, A., Chan, R., Valdez, J., & Ragland, J. D. (2004) · NeuroImage · doi:10.1016/j.neuroimage.2004.08.023 · Cited by 667
Small, D. M., Jones-Gotman, M., & Dagher, A. (2003) · NeuroImage · doi:10.1016/s1053-8119(03)00253-2 · Cited by 632
Ghrelin and the short- and long-term regulation of appetite and body weight
Cummings, D. E. (2006) · Physiology & Behavior · doi:10.1016/j.physbeh.2006.05.022 · Cited by 620
Homeostatic and hedonic signals interact in the regulation of food intake
Lutter, M., & Nestler, E. J. (2009) · The Journal of Nutrition · doi:10.3945/jn.108.097618 · Cited by 614 · cited 1×
“Non-homeostatic hedonic regulation of food intake Brain reward systems play a major role in feeding behavior (Saper et al., 2002; Lutter and Nestler, 2009).”
Rossi, M., Kim, M. S., Morgan, D. G. A., Small, C. J., Edwards, C. M. B., Sunter, D., Abusnana, S., Goldstone, A. P., Russell, S. H., Stanley, S. A., et al. (1998) · Endocrinology · doi:10.1210/endo.139.10.6332 · Cited by 576 · cited 1×
“Acutely, α-MSH (1 nmol/10 μl, ICV) decreases food intake in rats (Rossi et al., 1998).”
Pictures of appetizing foods activate gustatory cortices for taste and reward
Simmons, W. K., Martin, A., & Barsalou, L. W. (2005) · Cerebral Cortex · doi:10.1093/cercor/bhi038 · Cited by 569
Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction
Jiang, C., Xie, C., Lv, Y., Li, J., Krausz, K. W., Shi, J., Brocker, C. N., Desai, D., Amin, S. G., Bisson, W. H., et al. (2015) · Nature Communications · doi:10.1038/ncomms10166 · Cited by 559
Tsuchida, A., Yamauchi, T., Ito, Y., Hada, Y., Maki, T., Takekawa, S., Kamon, J., Kobayashi, M., Suzuki, R., Hara, K., et al. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402367200 · Cited by 550
Genotype Influences In Vivo Dopamine Transporter Availability in Human Striatum
Heinz, A. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00099-8 · Cited by 538
Body mass index and the risk of stroke in men
Kurth, T., Gaziano, J. M., Berger, K., Kase, C. S., Rexrode, K. M., Cook, N. R., Buring, J. E., & Manson, J. E. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.22.2557 · Cited by 524 · cited 1×
“Overweight and obese men exhibit increased risk for ischemic and hemorrhagic stroke (Kurth et al., 2002).”
Unraveling the central nervous system pathways underlying responses to leptin
Elmquist, J. K., Maratos-Flier, E., Saper, C. B., & Flier, J. S. (1998) · Nature Neuroscience · doi:10.1038/2164 · Cited by 520
Alhadeff, A. L., Rupprecht, L. E., & Hayes, M. R. (2012) · Endocrinology · doi:10.1210/en.2011-1443 · Cited by 515 · cited 3×
“Satiety signal: GLP-1 GLP-1, an incretin hormone and peripherally-derived satiety signal, has been linked centrally to non-homeostatic and motivational processes associated with food reward (Alhadeff et al., 2012; Dickson et al., 2012; Skibicka, 2013).”
Petry, N. M., Barry, D., Pietrzak, R. H., & Wagner, J. A. (2008) · Psychosomatic Medicine · doi:10.1097/psy.0b013e3181651651 · Cited by 494
Christopoulos, G., Perry, K. J., Morfis, M., Tilakaratne, N., Gao, Y., Fraser, N. J., Main, M. J., Foord, S. M., & Sexton, P. M. (1999) · Molecular Pharmacology · doi:10.1124/mol.56.1.235 · Cited by 486
Figlewicz, D. P., Evans, S. B., Murphy, J., Hoen, M., & Baskin, D. G. (2003) · Brain Research · doi:10.1016/s0006-8993(02)04087-8 · Cited by 482
Excessive sugar intake alters binding to dopamine and mu-opioid receptors in the brain
Colantuoni, C., Schwenker, J., McCarthy, J., Rada, P., Ladenheim, B., Cadet, J.-L., Schwartz, G. J., Moran, T. H., & Hoebel, B. G. (2001) · Neuroreport · doi:10.1097/00001756-200111160-00035 · Cited by 471 · cited 5×
“Binge eating and increased response to food-associated stimuli are associated frequently with obesity. μ-Opioid receptor availability in reward brain areas increases in response to binge eating of palatable foods (Colantuoni et al., 2001).”
InfluentialGhrelin action in the brain controls adipocyte metabolism
Theander-Carrillo, C. (2006) · Journal of Clinical Investigation · doi:10.1172/jci25811 · Cited by 465
Volkow, N. D., Wang, G., Fowler, J. S., Logan, J., Jayne, M., Franceschi, D., Wong, C., Gatley, S. J., Gifford, A. N., Ding, Y., et al. (2002) · Synapse · doi:10.1002/syn.10075 · Cited by 452
Roth, J. D., Roland, B. L., Cole, R. L., Trevaskis, J. L., Weyer, C., Koda, J. E., Anderson, C. M., Parkes, D. G., & Baron, A. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0706473105 · Cited by 436
Subcutaneous Oxyntomodulin Reduces Body Weight in Overweight and Obese Subjects
Wynne, K., Park, A. J., Small, C. J., Patterson, M., Ellis, S. M., Murphy, K. G., Wren, A. M., Frost, G. S., Meeran, K., Ghatei, M. A., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2390 · Cited by 435 · cited 2×
“Central mechanisms Hypothalamic neuronal circuits are implicated as the primary regulators of energy homeostasis and include the arcuate nucleus, which is located ventrally around the third ventricle of the brain (Wynne et al., 2005; Morrison and Berthoud, 2007).”
Arterburn, D. E., Bogart, A., Sherwood, N. E., Sidney, S., Coleman, K. J., Haneuse, S., O’Connor, P. J., Theis, M. K., Campos, G. M., McCulloch, D., et al. (2013) · Obesity Surgery · doi:10.1007/s11695-012-0802-1 · Cited by 426
The Catabolic Action of Insulin in the Brain Is Mediated by Melanocortins
Benoit, S. C., Air, E. L., Coolen, L. M., Strauss, R., Jackman, A., Clegg, D. J., Seeley, R. J., & Woods, S. C. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-20-09048.2002 · Cited by 417
Dickson, S. L., Shirazi, R. H., Hansson, C., Bergquist, F., Nissbrandt, H., & Skibicka, K. P. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6326-11.2012 · Cited by 414
Leinninger, G. M., Jo, Y.-H., Leshan, R. L., Louis, G. W., Yang, H., Barrera, J. G., Wilson, H., Opland, D. M., Faouzi, M. A., Gong, Y., et al. (2009) · Cell Metabolism · doi:10.1016/j.cmet.2009.06.011 · Cited by 412
Flint, A., Raben, A., Ersbøll, A., Holst, J., & Astrup, A. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801627 · Cited by 384 · cited 1×
“GLP-1 mediates appetite control via insulin release, glucagon inhibition as well as absorption and metabolism of macronutrients (Naslund et al., 1999; Flint et al., 2001).”
Common cellular and molecular mechanisms in obesity and drug addiction
Kenny, P. J. (2011) · Nature Reviews Neuroscience · doi:10.1038/nrn3105 · Cited by 382
Mahler, S. V., Smith, K. S., & Berridge, K. C. (2007) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301376 · Cited by 377 · cited 2×
“Anandamide enhanced hedonic 'liking' reactions (orofacial expressions) elicited by sucrose taste (Berridge, 2000; Mahler et al., 2007).”
InfluentialHormonal regulation of food intake
Stanley, S., Wynne, K., McGowan, B., & Bloom, S. (2005) · Physiological Reviews · doi:10.1152/physrev.00015.2004 · Cited by 372
Baggio, L. L., Huang, Q., Brown, T. J., & Drucker, D. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.063 · Cited by 372
Orlistat in the long-term treatment of obesity in primary care settings.
Hauptman, J. (2000) · Archives of Family Medicine · doi:10.1001/archfami.9.2.160 · Cited by 367
Kanoski, S. E., Fortin, S. M., Arnold, M., Grill, H. J., & Hayes, M. R. (2011) · Endocrinology · doi:10.1210/en.2011-0174 · Cited by 347 · cited 2×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript (9–39) (100 μg/2 μl, ICV), attenuated the decrease in food intake induced by GLP-1 agonists, exendin-4 (3 μg/kg, IP) and liraglutide (10 μg/kg, IP) (Kanoski et al., 2011).”
Inverse Association Between BMI and Prefrontal Metabolic Activity in Healthy Adults
Volkow, N. D., Wang, G., Telang, F., Fowler, J. S., Goldstein, R. Z., Alia‐Klein, N., Logan, J., Wong, C., Thanos, P. K., Ma, Y., et al. (2009) · Obesity · doi:10.1038/oby.2008.469 · Cited by 344
The FDA's Assessment of Two Drugs for Chronic Weight Management
Colman, E., Golden, J., Roberts, M., Egan, A., Weaver, J., & Rosebraugh, C. (2012) · New England Journal of Medicine · doi:10.1056/nejmp1211277 · Cited by 342
Fekete, C., Légrádi, G., Mihály, E., Huang, Q.-H., Tatro, J. B., Rand, W. M., Emerson, C. H., & Lechan, R. M. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-04-01550.2000 · Cited by 308
Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307 · cited 3×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript treated with pramlintide for a year exhibited weight loss relative to placebo-treated controls (Hollander et al., 2003).”
Davis, J. F., Tracy, A. L., Schurdak, J. D., Tschöp, M. H., Lipton, J. W., Clegg, D. J., & Benoit, S. C. (2008) · Behavioral Neuroscience · doi:10.1037/a0013111 · Cited by 307
The role of dopamine in motivation for food in humans: implications for obesity
Wang, G.-J., Volkow, N. D., & Fowler, J. S. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.5.601 · Cited by 285
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276
Whitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.724 · Cited by 264 · cited 1×
“A synthetic analog of amylin, pramlintide, is available for the treatment of both type 1- and type 2-diabetes (Whitehouse et al., 2002; Hollander et al., 2003).”
Dwoskin, L. P., Rauhut, A. S., King‐Pospisil, K. A., & Bardo, M. T. (2006) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2006.00178.x · Cited by 259 · cited 2×
“Buproprion ((±)-2-(tertbutylamino)-1-(3-chlorophenyly)propan-1-one) is an inhibitor of DA and NE transporters and is approved to treat depression and nicotine addiction (Dwoskin et al., 2006).”
Self-citationPeripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons
Wotherspoon, G., Fox, A., McIntyre, P., Colley, S., Bevan, S., & Winter, J. (2005) · Neuroscience · doi:10.1016/j.neuroscience.2005.06.009 · Cited by 251
Minireview: Glucagon in the Pathogenesis of Hypoglycemia and Hyperglycemia in Diabetes
Cryer, P. E. (2012) · Endocrinology · doi:10.1210/en.2011-1499 · Cited by 242
Richards, J. K., Simms, J. A., Steensland, P., Taha, S. A., Borgland, S. L., Bonci, A., & Bartlett, S. E. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1136-5 · Cited by 234
Kievit, P., Halem, H., Marks, D. L., Dong, J. Z., Glavas, M. M., Sinnayah, P., Pranger, L., Cowley, M. A., Grove, K. L., & Culler, M. D. (2013) · Diabetes · doi:10.2337/db12-0598 · Cited by 231
Role of orexin/hypocretin in reward-seeking and addiction: Implications for obesity
Cason, A. M., Smith, R. J., Tahsili-Fahadan, P., Moorman, D. E., Sartor, G. C., & Aston-Jones, G. (2010) · Physiology & Behavior · doi:10.1016/j.physbeh.2010.03.009 · Cited by 229
Cota, D., Steiner, M.-A., Marsicano, G., Cervino, C., Herman, J. P., Grübler, Y., Stalla, J., Pasquali, R., Lutz, B., Stalla, G. K., et al. (2007) · Endocrinology · doi:10.1210/en.2005-1649 · Cited by 205 · cited 1×
“Importantly, corticotrophin releasing hormone mRNA is increased in paraventricular nucleus of CB1 knockout mice (Cota et al., 2007).”
Evidence for defective mesolimbic dopamine exocytosis in obesity‐prone rats
Geiger, B. M., Behr, G. G., Frank, L. E., Caldera-Siu, A. D., Beinfeld, M. C., Kokkotou, E. G., & Pothos, E. N. (2008) · The FASEB Journal · doi:10.1096/fj.08-110759 · Cited by 194
Action and therapeutic potential of oxyntomodulin
Pocai, A. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2013.12.001 · Cited by 191
The central GLP-1: implications for food and drug reward
Skibicka, K. P. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00181 · Cited by 188
Chen, K. Y., Muniyappa, R., Abel, B. S., Mullins, K. P., Staker, P., Brychta, R. J., Zhao, X., Ring, M., Psota, T. L., Cone, R. D., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4024 · Cited by 174 · cited 2×
“A recent randomized, double-blind, placebo-controlled, crossover study examined the effects of RM-493 on resting energy expenditure in healthy obese adults (Chen et al., 2015).”
Richard, J. E., Anderberg, R. H., Göteson, A., Gribble, F. M., Reimann, F., & Skibicka, K. P. (2015) · PLOS ONE · doi:10.1371/journal.pone.0119034 · Cited by 168
Canagliflozin: effects in overweight and obese subjects without diabetes mellitus
Bays, H. E., Weinstein, R., Law, G., & Canovatchel, W. (2014) · Obesity · doi:10.1002/oby.20663 · Cited by 166
Mechanism Underlying the Weight Loss and Complications of Roux-en-Y Gastric Bypass. Review
Abdeen, G., & le Roux, C. (2016) · Obesity Surgery · doi:10.1007/s11695-015-1945-7 · Cited by 162
Tedesco, L., Valerio, A., Cervino, C., Cardile, A., Pagano, C., Vettor, R., Pasquali, R., Carruba, M. O., Marsicano, G., Lutz, B., et al. (2008) · Diabetes · doi:10.2337/db07-1623 · Cited by 145
Hyperglucagonemia increases resting metabolic rate in man during insulin deficiency
NAIR, K. S. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-5-896 · Cited by 141
Food‐Related Odor Probes of Brain Reward Circuits During Hunger: A Pilot fMRI Study
Bragulat, V., Dzemidzic, M., Bruno, C., Cox, C. A., Talavage, T., Considine, R. V., & Kareken, D. A. (2010) · Obesity · doi:10.1038/oby.2010.57 · Cited by 128
Use of prescription antiobesity drugs in the United States.
Hampp, C., Kang, E. M., & Borders‐Hemphill, V. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1342 · Cited by 103
Clemmensen, C., Finan, B., Fischer, K., Tom, R. Z., Legutko, B., Sehrer, L., Heine, D., Grassl, N., Meyer, C. W., Henderson, B., et al. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201404508 · Cited by 89 · cited 2×
“RM-493 and Liraglutide Efficacy of adjunctive RM-493 and liraglutide treatment was evaluated in an animal model of DIO (Clemmensen et al., 2015).”
InfluentialNeutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity
Meye, F. J., Trezza, V, Vanderschuren, L. J. M. J., Ramakers, G. M. J., & Adan, R. A. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.145 · Cited by 76
Calorigenic action of glucagon
DAVIDSON, I. W. F., SALTER, J. M., & BEST, C. H. (1957) · Nature · doi:10.1038/1801124a0 · Cited by 66
Sarkar, S., & Lechan, R. M. (2003) · Endocrinology · doi:10.1210/en.2002-220675 · Cited by 63
Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial
Kim, D. D., Krishnarajah, J., Lillioja, S., de Looze, F., Marjason, J., Proietto, J., Shakib, S., Stuckey, B. G. A., Vath, J. E., & Hughes, T. E. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12457 · Cited by 62
Cited by
The dopamine motive system: implications for drug and food addiction
Volkow, N. D., Wise, R. A., & Baler, R. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.130 · Cited by 939
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Obesity cardiomyopathy: evidence, mechanisms, and therapeutic implications
Ren, J., Wu, N. N., Wang, S., Sowers, J. R., & Zhang, Y. (2021) · Physiological Reviews · doi:10.1152/physrev.00030.2020 · Cited by 370
Nani, A., Murtaza, B., Sayed Khan, A., Khan, N. A., & Hichami, A. (2021) · Molecules · doi:10.3390/molecules26040985 · Cited by 321
Brown Adipose Tissue Energy Metabolism in Humans
Carpentier, A. C., Blondin, D. P., Virtanen, K. A., Richard, D., Haman, F., & Turcotte, É. E. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00447 · Cited by 321
Metadata
- Authors
- Narayanaswami, V., & Dwoskin, L. P.
- Venue
- Pharmacology & Therapeutics
- Publisher
- Elsevier BV
- Published
- 2017-02
- Volume
- 170
- Pages
- 116-147
- ISSN
- 0163-7258 (ISSN-L)
- OpenAlex
- W2534293284
- Cited by
- 186
- References
- 120
- FWCI
- 12.03
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.